FDA adds MAPLE-HCM data to aficamten label; AI-assisted POCUS shows no significant difference from visual reads; ACC backs earlier lipid lowering

A bedside cardiac monitor on a short stand, its dark screen showing a single rhythm trace.

The Food and Drug Administration (FDA) approved adding MAPLE-HCM data, comparing aficamten (Myqorzo) with metoprolol in obstructive hypertrophic cardiomyopathy, to the drug's label, Cytokinetics said Nov. 16. A meta-analysis found AI-assisted point-of-care ultrasound showed no statistically significant difference from visual assessment for reduced left ventricular function, the American College of Cardiology (ACC) issued a statement on earlier lipid lowering, and a meta-analysis found no recurrent stroke benefit from anticoagulants over aspirin after embolic stroke of undetermined source.

  • FDA Nov 16, 2026
    The Food and Drug Administration (FDA) approved a supplemental new drug application adding results of the phase 3 MAPLE-HCM trial to the prescribing information for aficamten (Myqorzo), Cytokinetics said Nov. 16. The trial randomized 175 patients with symptomatic obstructive hypertrophic cardiomyopathy to aficamten or metoprolol, each as monotherapy; the between-group difference in peak oxygen uptake, the primary end point, was 2.3 mL/kg/min (95% CI 1.5 to 3.1; P < .001), according to HCPLive. Hypertension occurred in 15% with aficamten versus 3% with metoprolol. The company said Myqorzo is the only cardiac myosin inhibitor with evidence comparing it with a beta-blocker.
  • AI Nov 17, 2026
    A systematic review and meta-analysis of 28 studies with 4,647 participants, published online Nov. 17 in the Journal of General Internal Medicine, compared three point-of-care ultrasound methods for detecting reduced left ventricular systolic function. Five studies of AI-assisted ultrasound gave a diagnostic odds ratio of 47.35 (95% CI 16.87 to 132.93), and nine studies of visual qualitative assessment gave 40.53 (95% CI 15.07 to 109.00). Meta-regression found no statistically significant differences among the three methods, which also included E-point septal separation.
  • AI Nov 19, 2026
    Siemens Healthineers received Food and Drug Administration (FDA) clearance for Syngo.CT Coronary Cockpit, software that analyzes coronary CT angiography data to support management of coronary artery disease, AuntMinnie reported Nov. 19. It uses AI-based segmentation, labeling and visualization to characterize the amount and morphology of plaque across the coronary tree or within individual lesions, and works with data from any CT scanner, according to the company. The report included no clinical validation data.
    Source: AuntMinnie
  • Guidelines Nov 19, 2026
    The American College of Cardiology (ACC) published a scientific statement online Nov. 19 in the Journal of the American College of Cardiology on lipid-lowering strategies in the era of early atherosclerosis detection. It said there is a strong rationale for both earlier and longer-term lipid lowering, and that clinicians should integrate short- and long-term risk, lipid burden, risk enhancers, imaging findings when appropriate and patient preferences in shared decisions. The statement said future studies and decision models should focus on individuals without clinical atherosclerotic cardiovascular disease.
  • Research Nov 20, 2026
    An individual participant data meta-analysis of four randomized trials with 13,970 patients with embolic stroke of undetermined source, published online Nov. 20 in The Lancet Neurology, found that anticoagulation did not reduce recurrent stroke compared with aspirin (adjusted hazard ratio 0.94, 95% CI 0.78 to 1.14). Major bleeding did not differ significantly (adjusted hazard ratio 1.19, 95% CI 0.52 to 2.73), with heterogeneity across studies. The authors said a possible benefit in patients with left atrial enlargement should be investigated in future trials.

The weekly innovation roundup for cardiology, published every Sunday for the week before; every item links to its sources. Latest cardiology news · All specialties

Latest news

Tagged cardiology, from the daily briefing

  1. Individual patient meta-analysis compares anticoagulants with aspirin after embolic stroke of undetermined source
  2. FDA clears Innovative Health to reprocess the OCTARAY cardiac mapping catheter
  3. FDA clears FOQUS ultrasound for automated patent foramen ovale screening that a single nurse can perform

See all the latest news